{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:49:14Z","timestamp":1783939754087,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jcv.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T16:26:56Z","timestamp":1507825616000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Optimized enzyme-linked immunosorbent assay for detecting cytomegalovirus infections during clinical trials of recombinant vaccines"],"prefix":"10.1016","volume":"96","author":[{"given":"Anke","family":"Pagnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gimenez-Fourage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseline","family":"Dubayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Arnaud-Barbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2017.10.004_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","article-title":"Priorities for CMV vaccine development","volume":"32","author":"Krause","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2017.10.004_bib0010","series-title":"Vaccines for the 21\u2009st Century: A Tool for Decisionmaking","article-title":"The national academies collection: reports funded by national institutes of health","author":"Institute of Medicine Committee to Study Priorities for Vaccine D","year":"2000"},{"key":"10.1016\/j.jcv.2017.10.004_bib0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2017.10.004_bib0020","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2017.10.004_bib0025","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"B vaccine is capable of boosting both antibody and CD4 T-Cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2017.10.004_bib0030","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1128\/JCM.37.1.179-188.1999","article-title":"Molecular fine-specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnostic assays","volume":"37","author":"Greijer","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0040","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1128\/JCM.31.3.724-726.1993","article-title":"Humoral immune response to human cytomegalovirus DNA polymerase","volume":"31","author":"Landini","year":"1993","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.30.1.201-206.1992","article-title":"Detection of cytomegalovirus antibodies by an enzyme-linked immunosorbent assay using recombinant polypeptides of the large phosphorylated tegument protein pp150","volume":"30","author":"Plachter","year":"1992","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0050","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/CVI.00317-13","article-title":"Pattern of the epitope-specific IgG\/IgM response against human cytomegalovirus in patients with multiple myeloma","volume":"20","author":"Bogner","year":"2013","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"10.1016\/j.jcv.2017.10.004_bib0055","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1083-8791(00)70072-3","article-title":"Humoral immune response to proteins of human cytomegalovirus latency-associated transcripts","volume":"6","author":"Landini","year":"2000","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.jcv.2017.10.004_bib0060","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1128\/JCM.33.7.1927-1930.1995","article-title":"The DNA-binding protein pUL57 of human cytomegalovirus is a major target antigen for the immunoglobulin M antibody response during acute infection","volume":"33","author":"Vornhagen","year":"1995","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2015.03.028","article-title":"Design and preclinical characterization of a novel vaccine adjuvant formulation consisting of a synthetic TLR4 agonist in a thermoreversible squalene emulsion","volume":"486","author":"Haensler","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jcv.2017.10.004_bib0070","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/JCM.29.9.1868-1872.1991","article-title":"Human cytomegalovirus structural proteins: immune reaction against pp150 synthetic peptides","volume":"29","author":"Landini","year":"1991","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0166-0934(88)90113-9","article-title":"Antibodies to human cytomegalovirus structural polypeptides during primary infection","volume":"22","author":"Landini","year":"1988","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2017.10.004_bib0080","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/JCM.32.4.981-986.1994","article-title":"Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens","volume":"32","author":"Vornhagen","year":"1994","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0085","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jcv.2005.09.020","article-title":"Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding","volume":"35","author":"Zhang","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.vaccine.2004.06.027","article-title":"Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine","volume":"23","author":"Zhang","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2017.10.004_bib0095","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"issue":"Suppl. 4","key":"10.1016\/j.jcv.2017.10.004_bib0100","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.10.004_bib0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1743-422X-6-45","article-title":"Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies","volume":"6","author":"Burbelo","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.jcv.2017.10.004_bib0110","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/JCM.30.10.2735-2739.1992","article-title":"Antibody responses to synthetic peptides from cytomegalovirus phosphoprotein 150","volume":"30","author":"Sundqvist","year":"1992","journal-title":"J. Clin. Microbiol."},{"issue":"Pt. 6","key":"10.1016\/j.jcv.2017.10.004_bib0115","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1099\/0022-1317-72-6-1409","article-title":"Mapping of serologically relevant regions of human cytomegalovirus phosphoprotein pp150 using synthetic peptides","volume":"72","author":"Novak","year":"1991","journal-title":"J. Gen. Virol."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653217302809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653217302809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T15:41:09Z","timestamp":1603122069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653217302809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":23,"alternative-id":["S1386653217302809"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2017.10.004","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimized enzyme-linked immunosorbent assay for detecting cytomegalovirus infections during clinical trials of recombinant vaccines","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}